These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37637419)

  • 21. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.
    Šimić I; Potočnjak I; Kraljičković I; Stanić Benić M; Čegec I; Juričić Nahal D; Ganoci L; Božina N
    Pharmacogenomics; 2016 Aug; 17(13):1385-9. PubMed ID: 27469576
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Maruf AA; Stein K; Arnold PD; Aitchison KJ; Müller DJ; Bousman C
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):33-45. PubMed ID: 33074724
    [No Abstract]   [Full Text] [Related]  

  • 23. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.
    Sukasem C; Hongkaew Y; Ngamsamut N; Puangpetch A; Vanwong N; Chamnanphon M; Chamkrachchangpada B; Sinrachatanant A; Limsila P
    J Clin Psychopharmacol; 2016 Apr; 36(2):141-6. PubMed ID: 26872113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical applications of CYP genotyping in psychiatry.
    Spina E; de Leon J
    J Neural Transm (Vienna); 2015 Jan; 122(1):5-28. PubMed ID: 25200585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.
    Manworren RC; Jeffries L; Pantaleao A; Seip R; Zempsky WT; Ruaño G
    Clin J Pain; 2016 Feb; 32(2):109-15. PubMed ID: 25803758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
    Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
    Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
    Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
    Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
    Bousman CA; Jaksa P; Pantelis C
    Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report.
    Wong DY; Fogel BL
    J Med Case Rep; 2021 Aug; 15(1):432. PubMed ID: 34407866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
    Bozina N; Jovanović N; Lovrić M; Medved V
    Ther Drug Monit; 2008 Dec; 30(6):748-51. PubMed ID: 18806696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.
    Fleeman N; Dundar Y; Dickson R; Jorgensen A; Pushpakom S; McLeod C; Pirmohamed M; Walley T
    Pharmacogenomics J; 2011 Feb; 11(1):1-14. PubMed ID: 20877299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical uses of pimozide.
    Tueth MJ; Cheong JA
    South Med J; 1993 Mar; 86(3):344-9. PubMed ID: 8451677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
    Dahl ML
    Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.